Total Payments
$1,663
2020 Payments
$11.69
Companies
17
Transactions
47
Medicare Patients
1,823
Medicare Billing
$209,937
Payment Breakdown by Category
Consulting$860.17 (51.7%)
Food & Beverage$791.22 (47.6%)
Education$11.69 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $860.17 | 2 | 51.7% |
| Food and Beverage | $791.22 | 44 | 47.6% |
| Education | $11.69 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ferring Pharmaceuticals Inc. | $860.17 | 2 | $0 (2019) |
| Allergan Inc. | $162.24 | 12 | $0 (2018) |
| PFIZER INC. | $132.94 | 1 | $0 (2018) |
| AbbVie, Inc. | $110.17 | 6 | $0 (2017) |
| Intercept Pharmaceuticals, Inc. | $79.59 | 4 | $0 (2017) |
| Ironwood Pharmaceuticals, Inc | $51.82 | 4 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $47.78 | 3 | $0 (2017) |
| Takeda Pharmaceuticals America, Inc. | $39.45 | 3 | $0 (2017) |
| Valeant Pharmaceuticals North America LLC | $34.92 | 2 | $0 (2017) |
| Janssen Biotech, Inc. | $28.95 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $11.69 | 1 | Janssen Pharmaceuticals, Inc ($11.69) |
| 2019 | $860.17 | 2 | Ferring Pharmaceuticals Inc. ($860.17) |
| 2018 | $169.37 | 3 | PFIZER INC. ($132.94) |
| 2017 | $621.85 | 41 | Allergan Inc. ($143.89) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 2 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/11/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/01/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/27/2017 | Allergan Inc. | VIBERZI (Drug) | Food and Beverage | In-kind items and services | $8.24 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/23/2017 | Takeda Pharmaceuticals America, Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: Lower GI | ||||||
| 04/20/2017 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug), VIBERZI, DELZICOL | Food and Beverage | In-kind items and services | $11.81 | General |
| Category: Gastroenterology | ||||||
| 04/17/2017 | Intercept Pharmaceuticals, Inc. | OCA (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Gastroenterology | ||||||
| 04/17/2017 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Immunology | ||||||
| 04/07/2017 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $12.48 | General |
| Category: THERAPY FOR CSID | ||||||
| 03/27/2017 | AbbVie, Inc. | Creon (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Endocrinology | ||||||
| 03/15/2017 | Takeda Pharmaceuticals America, Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: Lower GI | ||||||
| 03/13/2017 | Janssen Biotech, Inc. | STELARA (Biological), REMICADE | Food and Beverage | In-kind items and services | $10.82 | General |
| Category: Immunology | ||||||
| 03/09/2017 | AbbVie, Inc. | Viekira (Drug) | Food and Beverage | In-kind items and services | $4.03 | General |
| Category: Virology | ||||||
| 03/08/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Immunology | ||||||
| 03/06/2017 | Merck Sharp & Dohme Corporation | DIFICID (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/27/2017 | Takeda Pharmaceuticals America, Inc. | Amitiza (Drug) | Food and Beverage | In-kind items and services | $4.58 | General |
| Category: Lower GI | ||||||
| 02/24/2017 | Intercept Pharmaceuticals, Inc. | OCA (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: Gastroenterology | ||||||
| 02/23/2017 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug), VIBERZI | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Gastroenterology | ||||||
| 02/23/2017 | Intercept Pharmaceuticals, Inc. | OCA (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Gastroenterology | ||||||
| 02/13/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/30/2017 | Allergan Inc. | VIBERZI (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/26/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $8.72 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/12/2017 | Shire North American Group Inc | GATTEX (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: INTERNAL MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 370 | 430 | $211,477 | $43,269 |
| 2022 | 11 | 459 | 528 | $244,033 | $52,785 |
| 2021 | 11 | 493 | 586 | $262,256 | $58,144 |
| 2020 | 10 | 501 | 617 | $256,896 | $55,740 |
Total Patients
1,823
Total Services
2,161
Medicare Billing
$209,937
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 100 | $26,800 | $9,283 | 34.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 32 | 32 | $48,896 | $6,761 | 13.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 71 | 77 | $14,014 | $5,440 | 38.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 76 | $13,984 | $5,011 | 35.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 22 | 22 | $33,616 | $4,821 | 14.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 28 | $9,324 | $2,930 | 31.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $8,296 | $2,457 | 29.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $7,470 | $2,249 | 30.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $7,072 | $2,026 | 28.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 19 | 19 | $21,635 | $1,462 | 6.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $20,370 | $829.26 | 4.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 95 | 124 | $33,232 | $12,829 | 38.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 36 | 36 | $55,008 | $7,825 | 14.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 89 | 119 | $21,896 | $6,996 | 32.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $14,110 | $4,464 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 58 | $10,556 | $4,181 | 39.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 22 | $10,736 | $3,536 | 32.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 32 | 33 | $10,989 | $3,273 | 29.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 16 | 16 | $24,448 | $3,078 | 12.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 29 | 30 | $29,790 | $2,381 | 8.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 20 | 20 | $5,440 | $1,796 | 33.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 18 | 18 | $24,444 | $1,656 | 6.8% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 18 | 18 | $3,384 | $769.14 | 22.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 104 | 175 | $32,200 | $10,688 | 33.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 77 | $20,636 | $8,444 | 40.9% |
About Dr. Pietro Andres, M.D
Dr. Pietro Andres, M.D is a Gastroenterology healthcare provider based in Stratford, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588607386.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pietro Andres, M.D has received a total of $1,663 in payments from pharmaceutical and medical device companies, with $11.69 received in 2020. These payments were reported across 47 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($860.17).
As a Medicare-enrolled provider, Andres has provided services to 1,823 Medicare beneficiaries, totaling 2,161 services with total Medicare billing of $209,937. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Stratford, CT
- Active Since 06/13/2006
- Last Updated 01/28/2014
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1588607386
Products in Payments
- LINZESS (Drug) $169.60
- XELJANZ (Drug) $132.94
- Humira (Biological) $90.69
- OCA (Drug) $79.59
- VIBERZI (Drug) $44.46
- UCERIS (Drug) $34.92
- Entyvio (Biological) $34.87
- DIFICID (Drug) $34.29
- Sucraid (Drug) $22.97
- GATTEX (Drug) $22.74
- REMICADE (Biological) $18.13
- Creon (Drug) $15.45
- Donnatal (Drug) $15.30
- ZEPATIER (Drug) $13.49
- Cimzia (Drug) $12.65
- Trulance (Drug) $11.62
- STELARA (Biological) $10.82
- Amitiza (Drug) $4.58
- Viekira (Drug) $4.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Stratford
Dr. Promila Banerjee, M.d, M.D
Gastroenterology — Payments: $2,350
Gastroenterology $2,350
Howard Taubin, M.d, M.D
Gastroenterology — Payments: $2,003
Gastroenterology $2,003
Gregory Soloway, M.d, M.D
Gastroenterology — Payments: $947.79
Gastroenterology $947.79
Andrew Bedford, M.d, M.D
Gastroenterology — Payments: $747.51
Gastroenterology $747.51